The Integrative Genomics View (IGV) data revealed that the m6A level of HK2 and SLC2A1 (GLUT1) was higher in 5 CRC patients with METTL3 high expression than those with METTL3 low expression (Figure S4l), indicating that higher m6A level of HK2 and SLC2A1 (GLUT1) depends on METTL3 modification in CRC patients. Here, HK2 is linked to colorectal carcinoma.